Navigation Links
New indicator found for rapidly progressing form of deadly lung disease
Date:11/10/2010

ANN ARBOR, Mich. A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.

But researchers at the University of Michigan have discovered a receptor in the immune system that may serve as a marker for a rapidly progressing form of the disease, which causes the body to produce excess fibrous tissue in the lungs.

More than just signaling which patients have the more aggressive form of IPF a disease that claims about as many lives each year as breast cancer the researchers hope that targeting the TLR9 receptor may lead to new treatments that could slow or stop the illness' progression. The findings were published in the Nov. 10 issue of Science Translational Medicine.

"This finding has the potential to allow physicians caring for IPF patients to better determine the natural history of disease in individual patients, which could markedly facilitate decision making for the patient and their doctors," says pulmonologist Fernando J. Martinez, M.D., M.S., a professor of internal medicine at the University of Michigan Medical School and one of the study's two senior authors. "Moreover, it opens the potential for unique therapeutic approaches."

There is no known cause, cure, or FDA-approved treatment for IPF, and it remains virtually unknown to the general public, even though it is several times more common than cystic fibrosis and Lou Gehrig's Disease (or ALS), according to the Coalition for Pulmonary Fibrosis. Moreover, IPF only receives a fraction of the funding of those higher profile conditions.

The U-M led research, which drew on expertise from the Departments of Pathology, Internal Medicine and Radiology, found that TLR9, which stands for Toll-like receptor number 9, causes an increase in the growth of fibrotic tissue in the lungs when it recognizes a particular type of DNA frequently found in bacteria and viruses. Higher amounts of TLR9 were found in patients with rapidly progressing IPF than those with slowly progressing IPF.

The researchers also peered into the workings of IPF by transplanting the disease from humans into mice. Those experiments showed a greater fibrotic response to the TLR9-activating DNA using lung cells from patients with rapidly progressing IPF than with cells from people with slowly progressing IPF.

For more than two decades, the National Institutes of Health has funded the U-M group's investigation into the biological basis of IPF as well as novel ways to diagnose and treat patients who suffer from the devastating disorder. U-M's scientists and doctors study human cells to better understand how they are involved in the progressive scarring of the lungs. In addition, clinical testing is used to help better predict the stage of disease and the rate of progression in advising patients for therapy.

"The approach taken by our group really highlights the advantages of translational research in a complex human disease and shows the bench-to-bedside model is really a two-way street," notes Cory M. Hogaboam, Ph.D., a professor of pathology at U-M and the study's other senior investigator.


'/>"/>

Contact: Ian Demsky
idemsky@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
2. A new indicator of poor prognosis in node-negative colorectal cancer patients
3. Recurrence of breast cancer after more than 10 years is an important indicator of survival
4. Definitive diabetes indicator deceptively high in African-American children
5. 3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution
6. Study finds respiratory symptoms more reliable indicator of H1N1, not fever alone
7. Visual pattern preference may be indicator of autism in toddlers
8. One-third of antimalarial medicines sampled in 3 African nations found to be substandard
9. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
10. Highmark Foundation Awards $120,000 to the American Heart Association
11. Stuttering Foundation Hails New Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Milford, NJ (PRWEB) , ... December 02, 2016 , ... ... Nothing Water has some unique properties including its unmatched natural purity of just 6 ... as clean and crisp. , Nothing Water has been available in several ShopRite and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
(Date:11/30/2016)... PALMYRA, Wisconsin (PRWEB) , ... November 30, 2016 ... ... inclusion in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of ... consecutive year on the list, having ranked from 2008-2016. In addition, Standard Process ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... in the ECG Cables And ECG Leadwires Market owing to ... devices. On the other hand, the Asia-Pacific ... rate during the forecast period. The market players ... plc ( Ireland ), Koninklijke Philips N.V. ( ... ( China ), held major share of the ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 /PRNewswire/ ... research report "In Vitro Diagnostics/IVD Market by Product ... Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious ... the global market is valued at USD 60.22 ... grow at a CAGR of 5.5% during the ...
(Date:12/2/2016)... On Thursday, December 1st 2016, ... research, development and innovation in the biopharmaceutical industry at ... in the presence of Sergey Tsyb, Vice Minister of ... , Natalia Sanina, First Vice Chairman of the ... of Roszdravnadzor, National Service of Control in Healthcare, Sergey ...
Breaking Medicine Technology: